Preclinical biotech Lyell Immunopharma is looking to go public after a whirlwind year of big deals and big bucks raises as it looks to use cell therapy to beat solid tumors.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,